A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy
A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037, United States
Chongqing, Chongqing Municipality 400042, China
Chongqing, Chongqing Municipality 400060, China
Lanzhou, Gansu, China
Wuhan, Hubei 430022, China
Wuhan, Hubei 430030, China
Shengyang, Liaoning 110006, China
Brescia, 25123, Italy
Warsaw, 02034, Poland
Chelyabinsk, 454087, Russia
Kursk, 305035, Russia
Moscow, 143423, Russia
Ufa, 450054, Russia
Dnipro, 49102, Ukraine
Kharkiv, 61166, Ukraine
Lutsk, 43018, Ukraine
Sumy, 40022, Ukraine